September 16, 2026,Shanghai Escugen Biotechnology Co., Ltd. and Sovran Bio, Inc. announced that they have entered into an agreement to co‑develop a first‑in‑class, pan‑tumor bispecific antibody‑drug conjugate (ADC).

At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Ipsen disclosed preclinical research data for the first-in-class (FIC) antibody-drug conjugate (ADC) IPN60300 through two abstracts (Abstract 1665, Abstract 4444) and posters (Poster #1665, Poster #4444), with researchers from Shanghai Escugen Biotechnology Co., Ltd. (Escugen) listed as co-authors. IPN60300 is a novel ADC jointly developed by Escugen and Foreseen Technology (Beijing) Co., Ltd. (Foreseen), which was licensed to Ipsen by Foreseen in July 2024, with a total transaction value of 1.03 billion US dollars. Currently, the candidate is undergoing Phase I/II dose-escalation and expansion clinical trials (NCT07213817).